Keytruda and Ranitidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Ranitidine (ranitidine). Common drug interactions include somnolence among females and chills among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Ranitidine. It is created by eHealthMe based on reports of 83 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

On Aug, 03, 2026

83 people who take Keytruda and Ranitidine together, and have interactions are studied.

Keytruda and Ranitidine drug interactions.

What are the common drug interactions of Keytruda and Ranitidine, by gender? *:

female:

Somnolence (a state of near-sleep, a strong desire for sleep)
T-lymphocyte count increased
Viral infection
Weight decreased
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blood lactate dehydrogenase increased
Cerebral infarction (less blood supply to brain resulting tissue damage)
Discomfort
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Electrolyte imbalance

male:

Chills (felling of cold)
Arthralgia (joint pain)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Chest pain
Colitis (inflammation of colon)
Constipation
International normalised ratio increased
Myalgia (muscle pain)
Proctitis (inflammation of the rectum and anus)
Pyrexia (fever)

What are the common drug interactions of Keytruda and Ranitidine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Cough
Dyspnoea (difficult or laboured respiration)
Loss of consciousness
Memory impairment
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Myalgia (muscle pain)
Petit mal epilepsy (absence seizure)
Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
Thirst
Tremor (trembling or shaking movements in one or more parts of your body)

60+:

Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
Pneumonia
Hypertension (high blood pressure)
Malignant neoplasm progression (cancer tumour came back)
Supraventricular tachycardia (rapid heart rhythm originating at or above the atrioventricular node)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Chest pain
Colitis (inflammation of colon)
Constipation
Death

What are the existing conditions these people have? *

Pneumonia: 27 people, 32.53%
Non-Small Cell Lung Cancer Stage 0: 27 people, 32.53%
Lung Neoplasm Malignant (cancer tumour of lung): 10 people, 12.05%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 7 people, 8.43%
Squamous Cell Carcinoma (a cancer of a kind of epithelial cell): 5 people, 6.02%
Lung Cancer - Non-Small Cell (lung cancer): 5 people, 6.02%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Ranitidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously